comparemela.com

Latest Breaking News On - Peter grathwohl - Page 1 : comparemela.com

University of Tübingen, Boehringer Ingelheim launch AI and data science fellowship program

University of Tübingen, a leading member of Cyber Valley, Europe’s largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for top talents from around the world. Three to five fellowships will be awarded per year for up to three years with a target of nine to fifteen fellows in the program after five years.

University of Tübingen and Boehringer Ingelheim Join Forces to Lead AI and Data Science R&D for New Medical Breakthroughs

University of Tübingen, a leading member of Cyber Valley, Europe's largest Artificial Intelligence (AI) research consortium and Boehringer Ingelheim launch an AI and data science fellowship program for

Evotec Launches BeLAB2122 , Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb

Evotec Launches BeLAB2122 , Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Evotec launches beLAB2122 , translating academic innovation from leading German life science region

Evotec launches beLAB2122 , translating academic innovation from leading German life science region
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

Evotec Launches BeLAB2122 , Translating Academic Innovation from Leading German Life Science Region in Collaboration with Bristol Myers Squibb

Published: Apr 13, 2021 beLAB2122 LEVERAGES ACADEMIC INNOVATION FROM THE RHINE-MAIN-NECKAR REGION OF GERMANY EVOTEC PROVIDES ITS ALL-MODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC PROJECTS FROM THE UNIVERSITIES OF FRANKFURT, HEIDELBERG AND TÜBINGEN AS WELL AS FROM THE EMBL AND THE DKFZ BRISTOL MYERS SQUIBB TO PROVIDE FUNDING AND COMMERCIAL PERSPECTIVES FOR ACADEMIC ASSETS DEVELOPED BY beLAB2122 HAMBURG, GERMANY / / April 13, 2021 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has launched beLAB2122, a translational $ 20 million BRIDGE in collaboration with Bristol-Myers Squibb Company (NYSE: BMY). beLAB2122 brings together leading academic institutions from the Rhine-Main-Neckar region of Germany with the goal of efficiently advancing first-in-class therapeutic options across all therapeutic areas and formats into investable drug discovery and early development projects.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.